Review



anti chrebp  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Proteintech anti chrebp
    Anti Chrebp, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 26 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chrebp/MLXIPL+Antibody/10__1016_slash_j__jff__2026__107485-73-0-4
    Average 93 stars, based on 26 article reviews
    anti chrebp - by Bioz Stars, 2026-11
    93/100 stars

    Images

    Related Articles

    Control:

    Article Title: Postbiotics Prepared Using Lactobacillus reuteri Ameliorates Ethanol-Induced Liver Injury by Regulating the FXR/SHP/SREBP-1c Axis.
    Article Snippet: Scope: While probiotics-based therapies have exhibited potential in alleviating alcohol-associated liver disease (ALD), the specific role of postbiotics derived from Lactobacillus reuteri (L. reuteri) in ALD remains elusive.. This study aims to investigate the impact of postbiotics on ameliorating alcohol-induced hepatic steatosis and the underlying mechanisms.. Methods and results: Using network pharmacology, the study elucidates the targets and pathways impacted by postbiotics from L. reuteri, identifying the farnesoid X receptor (FXR) as a promising target for postbiotics against ALD, and lipid metabolism and alcoholism act as crucial pathways associated with postbiotics-targeting ALD.

    Article Title: Lin28 enhances de novo fatty acid synthesis to promote cancer progression via SREBP ‐1
    Article Snippet: .. Antibodies for Lin28A, Lin28B, HK2, FASN, ACC1, ACLY, CPT1A, MCAD, SCAD, CD36, FABP1, FABP5, FATP2, FATP5, SREBP‐1, SCAP, ChREBP, LXRα, DGCR8, CHOP (Proteintech; 1:1,000); SCD1 (Abcam; 1:1,000); PDK1 (Enzo Life Sciences; 1:1,000); and ATF6 (Santa Cruz Biotechnology; 1:1,000) were used for blotting. β‐Actin (Abmart; 1:5,000) served as loading control. .. HRP‐conjugated anti‐rabbit and anti‐mouse (Bio‐Rad) secondary antibodies were used.

    Incubation:

    Article Title: Postbiotics Prepared Using Lactobacillus reuteri Ameliorates Ethanol-Induced Liver Injury by Regulating the FXR/SHP/SREBP-1c Axis.
    Article Snippet: Scope: While probiotics-based therapies have exhibited potential in alleviating alcohol-associated liver disease (ALD), the specific role of postbiotics derived from Lactobacillus reuteri (L. reuteri) in ALD remains elusive.. This study aims to investigate the impact of postbiotics on ameliorating alcohol-induced hepatic steatosis and the underlying mechanisms.. Methods and results: Using network pharmacology, the study elucidates the targets and pathways impacted by postbiotics from L. reuteri, identifying the farnesoid X receptor (FXR) as a promising target for postbiotics against ALD, and lipid metabolism and alcoholism act as crucial pathways associated with postbiotics-targeting ALD.

    other:

    Article Title: 6-Methyl flavone inhibits Nogo-B expression and improves high fructose diet-induced liver injury in mice.
    Article Snippet: Excessive fructose consumption increases hepatic de novo lipogenesis, resulting in cellular stress, inflammation and liver injury.. Nogo-B is a resident protein of the endoplasmic reticulum that regulates its structure and function.. Hepatic Nogo-B is a key protein in glycolipid metabolism, and inhibition of Nogo-B has protective effects against metabolic syndrome, thus small molecules that inhibit Nogo-B have therapeutic benefits for glycolipid metabolism disorders.



    Similar Products

    94
    Shanghai Korain Biotech Co Ltd carbohydrate response element binding protein chrebp
    Carbohydrate Response Element Binding Protein Chrebp, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chrebp/Rat+Carbohydrate+Response+Element+Binding+Protein/10__1038_slash_s41598___026___72996___9-90-6-34
    Average 94 stars, based on 1 article reviews
    carbohydrate response element binding protein chrebp - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    Proteintech anti chrebp
    Anti Chrebp, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chrebp/MLXIPL+Antibody/10__1016_slash_j__jff__2026__107485-73-0-4
    Average 93 stars, based on 1 article reviews
    anti chrebp - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    86
    Takeda chrebp
    Chrebp, supplied by Takeda, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chrebp/chrebp/pm42047761-431-13-8
    Average 86 stars, based on 1 article reviews
    chrebp - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier



    89
    Thermo Fisher gene exp mlxipl hs00975714 m1
    LYPLAL1 knockout alters the expression of metabolic regulators and mitochondrial β-oxidation processes. A: mRNA levels of transcription factors <t>MLXIPL</t> and PPARα without oleic acid (OA) and with 200 μM OA. B and C: mRNA levels of (B) de novo lipogenesis genes and (C) β-oxidation genes with and without 200 μM OA treatment. D: Representative histograms and relative mean fluorescence intensity (MFI) showing protein levels of major β-oxidation enzymes ACADVL, ACADM, and HADHA without oleic acid and with 200 μM OA. E: Seahorse XF assay for mitochondrial oxygen consumption rate (OCR) in vehicle or etomoxir treated HuH-7 and LYPLAL1 KO cells without oleic acid and with 200 μM OA. Port A: Etomoxir (4 μM), port B: Oligomycin (1.5 μM), port C: FCCP (0.5 μM), and port D: Rotenone/antimycin A (0.5 μM). F: Maximal oxygen consumption rate (OCR) with vehicle or etomoxir treated HuH-7 and LYPLAL1 KO cells without oleic acid and with 200 μM OA. LYP KO = LYPLAL1 KO, Eto = Etomoxir. G: Vehicle treated (<1% DMSO) and etomoxir treated (100 μM) HuH-7 and LYPLAL1 KO cells with 200 μM OA. Cells were treated with etomoxir and oleic acid for 24 h. Data represented as mean ± S.E.M. ns: P > 0.05, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001.
    Gene Exp Mlxipl Hs00975714 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 89/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chrebp/Gene+Exp%2E+MLXIPL%2C+Hs00975714_m1/pmc13090602-67-7--1
    Average 89 stars, based on 1 article reviews
    gene exp mlxipl hs00975714 m1 - by Bioz Stars, 2026-11
    89/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc anti chrebp
    LYPLAL1 knockout alters the expression of metabolic regulators and mitochondrial β-oxidation processes. A: mRNA levels of transcription factors <t>MLXIPL</t> and PPARα without oleic acid (OA) and with 200 μM OA. B and C: mRNA levels of (B) de novo lipogenesis genes and (C) β-oxidation genes with and without 200 μM OA treatment. D: Representative histograms and relative mean fluorescence intensity (MFI) showing protein levels of major β-oxidation enzymes ACADVL, ACADM, and HADHA without oleic acid and with 200 μM OA. E: Seahorse XF assay for mitochondrial oxygen consumption rate (OCR) in vehicle or etomoxir treated HuH-7 and LYPLAL1 KO cells without oleic acid and with 200 μM OA. Port A: Etomoxir (4 μM), port B: Oligomycin (1.5 μM), port C: FCCP (0.5 μM), and port D: Rotenone/antimycin A (0.5 μM). F: Maximal oxygen consumption rate (OCR) with vehicle or etomoxir treated HuH-7 and LYPLAL1 KO cells without oleic acid and with 200 μM OA. LYP KO = LYPLAL1 KO, Eto = Etomoxir. G: Vehicle treated (<1% DMSO) and etomoxir treated (100 μM) HuH-7 and LYPLAL1 KO cells with 200 μM OA. Cells were treated with etomoxir and oleic acid for 24 h. Data represented as mean ± S.E.M. ns: P > 0.05, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001.
    Anti Chrebp, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chrebp/ChREBP+Antibody/bio_rxiv__64898__2026__03__27__714471-272-15-19
    Average 94 stars, based on 1 article reviews
    anti chrebp - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Santa Cruz Biotechnology chrebp
    LYPLAL1 knockout alters the expression of metabolic regulators and mitochondrial β-oxidation processes. A: mRNA levels of transcription factors <t>MLXIPL</t> and PPARα without oleic acid (OA) and with 200 μM OA. B and C: mRNA levels of (B) de novo lipogenesis genes and (C) β-oxidation genes with and without 200 μM OA treatment. D: Representative histograms and relative mean fluorescence intensity (MFI) showing protein levels of major β-oxidation enzymes ACADVL, ACADM, and HADHA without oleic acid and with 200 μM OA. E: Seahorse XF assay for mitochondrial oxygen consumption rate (OCR) in vehicle or etomoxir treated HuH-7 and LYPLAL1 KO cells without oleic acid and with 200 μM OA. Port A: Etomoxir (4 μM), port B: Oligomycin (1.5 μM), port C: FCCP (0.5 μM), and port D: Rotenone/antimycin A (0.5 μM). F: Maximal oxygen consumption rate (OCR) with vehicle or etomoxir treated HuH-7 and LYPLAL1 KO cells without oleic acid and with 200 μM OA. LYP KO = LYPLAL1 KO, Eto = Etomoxir. G: Vehicle treated (<1% DMSO) and etomoxir treated (100 μM) HuH-7 and LYPLAL1 KO cells with 200 μM OA. Cells were treated with etomoxir and oleic acid for 24 h. Data represented as mean ± S.E.M. ns: P > 0.05, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001.
    Chrebp, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chrebp/ChREBP+Antibody/pmc12912586-28-2-8
    Average 94 stars, based on 1 article reviews
    chrebp - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    Experimental validation of MLXIPL upregulation and metabolic network consistency in diabetic models. (A–C) Assessment of ChREBP expression in kidney tissues from db/m and db/db mice. Representative Western blots (A) and densitometric quantification (B) of ChREBP protein levels. For animal Western blot analyses, densitometric quantification was performed using all 12 mice per group. Full-length immunoblot images are provided in <xref ref-type=Supplementary Figure 4 . (C) Relative mRNA expression of Mlxipl . (D–F) Assessment of ChREBP expression in primary proximal tubular epithelial cells (PTECs) under normal glucose (NC) and high glucose (HG) conditions. Representative Western blots (D) , protein quantification (E) , and mRNA levels (F) . (G) Representative immunohistochemistry (IHC) staining of ChREBP in mouse kidney sections. Scale bar: 100 μm. (H) Representative immunofluorescence (IF) staining of ChREBP (green) in PTECs; nuclei were counterstained with DAPI (blue). Scale bar: 50 μm. (I) Relative mRNA expression of MLXIPL -interacting metabolic genes in mouse kidneys. (J) Pearson correlation analysis between Mlxipl expression and downstream metabolic targets in kidney tissues.Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. " width="100%" height="100%">

    Journal: Frontiers in Endocrinology

    Article Title: Integrated causal inference, kidney transcriptomics, and experimental validation identify ChREBP ( MLXIPL ) as a driver of maladaptive metabolic remodeling in diabetic kidney disease

    doi: 10.3389/fendo.2026.1809567

    Figure Lengend Snippet: Experimental validation of MLXIPL upregulation and metabolic network consistency in diabetic models. (A–C) Assessment of ChREBP expression in kidney tissues from db/m and db/db mice. Representative Western blots (A) and densitometric quantification (B) of ChREBP protein levels. For animal Western blot analyses, densitometric quantification was performed using all 12 mice per group. Full-length immunoblot images are provided in Supplementary Figure 4 . (C) Relative mRNA expression of Mlxipl . (D–F) Assessment of ChREBP expression in primary proximal tubular epithelial cells (PTECs) under normal glucose (NC) and high glucose (HG) conditions. Representative Western blots (D) , protein quantification (E) , and mRNA levels (F) . (G) Representative immunohistochemistry (IHC) staining of ChREBP in mouse kidney sections. Scale bar: 100 μm. (H) Representative immunofluorescence (IF) staining of ChREBP (green) in PTECs; nuclei were counterstained with DAPI (blue). Scale bar: 50 μm. (I) Relative mRNA expression of MLXIPL -interacting metabolic genes in mouse kidneys. (J) Pearson correlation analysis between Mlxipl expression and downstream metabolic targets in kidney tissues.Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

    Article Snippet: Sections were blocked with 1% BSA and incubated with anti-ChREBP antibody (Novus Biologicals, NB400-135; IHC dilution 1:200), followed by appropriate secondary antibodies and chromogenic development.

    Techniques: Biomarker Discovery, Expressing, Western Blot, Immunohistochemistry, Immunofluorescence, Staining

    LYPLAL1 knockout alters the expression of metabolic regulators and mitochondrial β-oxidation processes. A: mRNA levels of transcription factors MLXIPL and PPARα without oleic acid (OA) and with 200 μM OA. B and C: mRNA levels of (B) de novo lipogenesis genes and (C) β-oxidation genes with and without 200 μM OA treatment. D: Representative histograms and relative mean fluorescence intensity (MFI) showing protein levels of major β-oxidation enzymes ACADVL, ACADM, and HADHA without oleic acid and with 200 μM OA. E: Seahorse XF assay for mitochondrial oxygen consumption rate (OCR) in vehicle or etomoxir treated HuH-7 and LYPLAL1 KO cells without oleic acid and with 200 μM OA. Port A: Etomoxir (4 μM), port B: Oligomycin (1.5 μM), port C: FCCP (0.5 μM), and port D: Rotenone/antimycin A (0.5 μM). F: Maximal oxygen consumption rate (OCR) with vehicle or etomoxir treated HuH-7 and LYPLAL1 KO cells without oleic acid and with 200 μM OA. LYP KO = LYPLAL1 KO, Eto = Etomoxir. G: Vehicle treated (<1% DMSO) and etomoxir treated (100 μM) HuH-7 and LYPLAL1 KO cells with 200 μM OA. Cells were treated with etomoxir and oleic acid for 24 h. Data represented as mean ± S.E.M. ns: P > 0.05, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001.

    Journal: Journal of Lipid Research

    Article Title: LYPLAL1 rare loss-of-function variants in humans and deletion in human hepatoma cells protect against MASLD

    doi: 10.1016/j.jlr.2026.101013

    Figure Lengend Snippet: LYPLAL1 knockout alters the expression of metabolic regulators and mitochondrial β-oxidation processes. A: mRNA levels of transcription factors MLXIPL and PPARα without oleic acid (OA) and with 200 μM OA. B and C: mRNA levels of (B) de novo lipogenesis genes and (C) β-oxidation genes with and without 200 μM OA treatment. D: Representative histograms and relative mean fluorescence intensity (MFI) showing protein levels of major β-oxidation enzymes ACADVL, ACADM, and HADHA without oleic acid and with 200 μM OA. E: Seahorse XF assay for mitochondrial oxygen consumption rate (OCR) in vehicle or etomoxir treated HuH-7 and LYPLAL1 KO cells without oleic acid and with 200 μM OA. Port A: Etomoxir (4 μM), port B: Oligomycin (1.5 μM), port C: FCCP (0.5 μM), and port D: Rotenone/antimycin A (0.5 μM). F: Maximal oxygen consumption rate (OCR) with vehicle or etomoxir treated HuH-7 and LYPLAL1 KO cells without oleic acid and with 200 μM OA. LYP KO = LYPLAL1 KO, Eto = Etomoxir. G: Vehicle treated (<1% DMSO) and etomoxir treated (100 μM) HuH-7 and LYPLAL1 KO cells with 200 μM OA. Cells were treated with etomoxir and oleic acid for 24 h. Data represented as mean ± S.E.M. ns: P > 0.05, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001.

    Article Snippet: Probes used: GAPDH (Hs02786624_g1), ELF1 (Hs01111177_m1), MLXIPL (Hs00975714_m1), PPARα (Hs00947536_m1), ACACA (Hs01046047_m1), ACLY (Hs00982738_m1), FASN (Hs01005622_m1), SCD (Hs01682761_m1), CPT1A (Hs00912671_m1), ACADL (Hs00155630_m1), ACADM (Hs00936584_m1), ACADVL (Hs00825606_g1), EHHADH (Hs00157347_m1), HADHA (Hs00426191_m1), CD36 (Hs00354519_m1), and FABP1 (Hs00155026_m1).

    Techniques: Knock-Out, Expressing, Fluorescence, XF Assay

    Effects of CRISPRa induced LYPLAL1 overexpression on lipid accumulation. A: Relative mRNA levels of LYPLAL1 and (B) Representative images of HuH-7 expressing dCas9-SAM (left column marked as vector) and LYPLAL1a (right column) cells stained with Hoechst (blue), CellMask (red), and LipidTOX™ Green (green). Images shown for cells treated with 250 μM oleic acid (OA). Scale bars = 50 μm. C: Quantified integrated intensity (using CellProfiler) of lipid-stained cells at various doses of oleic acid. D: Relative mRNA levels of transcription factors MLXIPL and PPARα and β-oxidation regulator CPT1A without oleic acid and with 200 μM OA. Data represented as mean ± S.E.M. ns: P > 0.05, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001.

    Journal: Journal of Lipid Research

    Article Title: LYPLAL1 rare loss-of-function variants in humans and deletion in human hepatoma cells protect against MASLD

    doi: 10.1016/j.jlr.2026.101013

    Figure Lengend Snippet: Effects of CRISPRa induced LYPLAL1 overexpression on lipid accumulation. A: Relative mRNA levels of LYPLAL1 and (B) Representative images of HuH-7 expressing dCas9-SAM (left column marked as vector) and LYPLAL1a (right column) cells stained with Hoechst (blue), CellMask (red), and LipidTOX™ Green (green). Images shown for cells treated with 250 μM oleic acid (OA). Scale bars = 50 μm. C: Quantified integrated intensity (using CellProfiler) of lipid-stained cells at various doses of oleic acid. D: Relative mRNA levels of transcription factors MLXIPL and PPARα and β-oxidation regulator CPT1A without oleic acid and with 200 μM OA. Data represented as mean ± S.E.M. ns: P > 0.05, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001.

    Article Snippet: Probes used: GAPDH (Hs02786624_g1), ELF1 (Hs01111177_m1), MLXIPL (Hs00975714_m1), PPARα (Hs00947536_m1), ACACA (Hs01046047_m1), ACLY (Hs00982738_m1), FASN (Hs01005622_m1), SCD (Hs01682761_m1), CPT1A (Hs00912671_m1), ACADL (Hs00155630_m1), ACADM (Hs00936584_m1), ACADVL (Hs00825606_g1), EHHADH (Hs00157347_m1), HADHA (Hs00426191_m1), CD36 (Hs00354519_m1), and FABP1 (Hs00155026_m1).

    Techniques: Over Expression, Expressing, Plasmid Preparation, Staining